Cingulate Inc.
NASDAQ:CINGBiotechnology
-$0.05 today
- Market cap
- $76.46M
- Beta
- -0.91
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$5.10
Volume 0.95M
Average 0.46M
CING Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Cingulate Inc.NASDAQ: CING
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $121.19K fell 26.7% year over year, behind the -24.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -26.7% toward the trailing-twelve-month pace of -24.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 540.89K USD
- Year-over-year change
- -17.2%
- 4-year CAGR
- -6.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 540.89K | -17.2% |
| FY2024 | 2024-12-31 | 653.09K | +12.0% |
| FY2023 | 2023-12-31 | 582.92K | +47.9% |
| FY2022 | 2022-12-31 | 394.01K | -44.4% |
| FY2021 | 2021-12-31 | 708.32K | — |
Depreciation & Amortization vs competitors
How CING compares with its peers on the latest reported figures
- CING's LTM Mar 2026 depreciation & amortization of $496.79K is the highest of the 2 companies compared; the peer median is $0.
- Its year-over-year change of -24.1% is the highest of 2, against a peer median of -100.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $496.79K | -24.1% | +11.1% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding CING) | $0 | -100.0% | — | — | |
Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.41M | 9M | 15.49M | 9.45M | 9.77M |
| Selling, General & Admin | 12.27M | 8.51M | 7.27M | 6.2M | 10.16M |
| Operating Expenses | 20.68M | 17.5M | 22.76M | 15.64M | 19.94M |
| Depreciation & Amortization | 708.32K | 394.01K | 582.92K | 653.09K | 540.89K |
| EBITDA | (19.97M) | (17.11M) | (22.18M) | (14.99M) | (19.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.68M) | (17.5M) | (22.76M) | (15.64M) | (19.94M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 175 | 775.76K | 0 | 369.27K |
| Interest Expense | 33.41K | 174K | 0 | 0 | 924.45K |
| Other Income / Expenses | (30.59K) | (174.51K) | (775.76K) | (914.63K) | (2.51M) |
| Income Before Tax | (20.71M) | (17.68M) | (23.53M) | (16.56M) | (22.45M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.71M) | (17.68M) | (23.53M) | (16.56M) | (22.45M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (55.80) | (31.20) | (311.99) | (10.20) | (4.13) |
| EPS (Diluted) | (55.80) | (31.20) | (311.99) | (10.20) | (4.13) |
| Weighted Avg Shares | 1.41M | 1.41M | 2.26M | 3.81M | 5.43M |
| Weighted Avg Shares (Diluted) | 1.41M | 1.41M | 2.26M | 3.81M | 5.43M |
Cingulate Inc.
NASDAQ:CING
Intrinsic Alpha fair value
Locked
Current Price
$5.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.